EA200100494A1 - Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гипатита-b - Google Patents

Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гипатита-b

Info

Publication number
EA200100494A1
EA200100494A1 EA200100494A EA200100494A EA200100494A1 EA 200100494 A1 EA200100494 A1 EA 200100494A1 EA 200100494 A EA200100494 A EA 200100494A EA 200100494 A EA200100494 A EA 200100494A EA 200100494 A1 EA200100494 A1 EA 200100494A1
Authority
EA
Eurasian Patent Office
Prior art keywords
virus
hepatitis
synthesis
human immunodeficiency
activities
Prior art date
Application number
EA200100494A
Other languages
English (en)
Other versions
EA005097B1 (ru
EA200100494A3 (ru
Inventor
Раймонд Ф. Шинази
Чунг К. Чу
Джинфа Ду
Original Assignee
Эмори Юниверсити
Дзе Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмори Юниверсити, Дзе Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк. filed Critical Эмори Юниверсити
Publication of EA200100494A1 publication Critical patent/EA200100494A1/ru
Publication of EA200100494A3 publication Critical patent/EA200100494A3/ru
Publication of EA005097B1 publication Critical patent/EA005097B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Представляется способ получения 1,3-оксаселеноланнуклеозида или его фармацевтически приемлемой соли, эффективного при лечении инфекций ВИЧ, инфекций вируса гепатита-В или аномальной пролиферации клеток у человека и других животных.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100494A 1997-03-19 1998-03-19 Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гепатита-b EA005097B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4126597P 1997-03-19 1997-03-19
PCT/US1998/005517 WO1998041522A1 (en) 1997-03-19 1998-03-19 Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides

Publications (3)

Publication Number Publication Date
EA200100494A1 true EA200100494A1 (ru) 2001-10-22
EA200100494A3 EA200100494A3 (ru) 2002-02-28
EA005097B1 EA005097B1 (ru) 2004-10-28

Family

ID=21915638

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200100494A EA005097B1 (ru) 1997-03-19 1998-03-19 Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гепатита-b
EA199900843A EA001920B1 (ru) 1997-03-19 1998-03-19 Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA199900843A EA001920B1 (ru) 1997-03-19 1998-03-19 Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b

Country Status (10)

Country Link
US (3) US6071922A (ru)
EP (1) EP0970078B1 (ru)
CN (1) CN1196701C (ru)
AT (1) ATE267198T1 (ru)
AU (1) AU739240B2 (ru)
CA (1) CA2287370C (ru)
DE (1) DE69823984T2 (ru)
EA (2) EA005097B1 (ru)
ES (1) ES2221164T3 (ru)
WO (1) WO1998041522A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1382343E (pt) * 1998-11-02 2010-03-10 Gilead Sciences Inc Terapia de combinação para tratamento do vírus da hepatite b
NO20001903L (no) 1999-04-14 2000-10-16 Dow Chemical Co Polyuretan-filmer fremstilt fra polyuretan-dispersjoner
NO20001904L (no) 1999-04-14 2000-10-16 Dow Chemical Co Polyuretanfilmer fremstilt ved elektrolytisk utfelling fra polyuretandispersjoner
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
WO2001092282A2 (en) 2000-05-26 2001-12-06 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
CN102911166B (zh) 2001-03-01 2016-08-17 基利得科学公司 顺-ftc的多晶型物及其它晶型
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CN105039489A (zh) * 2004-02-03 2015-11-11 埃莫里大学 制备1,3-二氧戊环核苷的方法
EP2059198B1 (en) 2006-09-06 2014-01-15 Cook Medical Technologies LLC Stents with connectors and stabilizing biodegradable elements
JP2013523765A (ja) 2010-04-01 2013-06-17 イデニク プハルマセウティカルス，インコーポレイテッド ウイルス感染の治療のための化合物及び医薬組成物
KR101021294B1 (ko) 2010-10-11 2011-03-11 공주대학교 산학협력단 신규한 셀레닐 메틸 우라실 화합물 및 이를 이용한 방사선 치료 증진제 및 의약 조성물
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
CN103906759A (zh) 2011-09-12 2014-07-02 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
AU2015343805B2 (en) * 2014-11-03 2018-11-22 Nicolai Vladimirovich Bovin Antimicrobial surface treatment

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
JPH02500017A (ja) * 1986-09-30 1990-01-11 ツアーンラートファブリーク、フリードリッヒスハーフェン、アクチエンゲゼルシャフト ブレーキ一体形の走行車伝動装置
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
DK0458937T3 (da) * 1989-12-20 1998-02-23 Biotech Australia Pty Ltd Varianter af PAI-2
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) * 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
JP3479068B2 (ja) * 1991-03-06 2003-12-15 エモリー・ユニバーシティ ５−フルオロ−２’−デオキシ−３’−チアシチジンのｂ型肝炎治療への使用
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues

Also Published As

Publication number Publication date
CA2287370C (en) 2010-02-09
US6071922A (en) 2000-06-06
EP0970078B1 (en) 2004-05-19
US6197777B1 (en) 2001-03-06
WO1998041522A1 (en) 1998-09-24
EA001920B1 (ru) 2001-10-22
ATE267198T1 (de) 2004-06-15
AU6866598A (en) 1998-10-12
EP0970078A1 (en) 2000-01-12
AU739240B2 (en) 2001-10-04
EA199900843A1 (ru) 2000-04-24
DE69823984D1 (de) 2004-06-24
EA005097B1 (ru) 2004-10-28
CN1255132A (zh) 2000-05-31
CN1196701C (zh) 2005-04-13
CA2287370A1 (en) 1998-09-24
ES2221164T3 (es) 2004-12-16
US6590107B1 (en) 2003-07-08
EA200100494A3 (ru) 2002-02-28
DE69823984T2 (de) 2005-05-12

Similar Documents

Publication Publication Date Title
EA200100494A3 (ru) Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гипатита-b
HK1014663A1 (en) Enantiomerically pure beta-d-dioxolane nucleosides with selective anti-hepatitis b virus activity
EP1808434A3 (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine fo the treatment of hepatitis B
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
DE69635656D1 (de) 5-fluoro-2',3'-ungesättigte pyrimidinnucleoside
ZA97721B (en) Methods for retreatment of patients afflicted with hepatitis C using consensus interferon.
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
BG91270A (bg) Антивирусно и антибактериално средство и метод за използването му
AU6924796A (en) 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c
DK92788A (da) Anvendelse af 3'-deoxy-3'-flourguanosider til fremstilling af laegemidler mod retrovira
MY127808A (en) Use of dideoxy nucleoside analogues in the treatment of viral infections
DK1280813T3 (da) Antivirale pyrimidin-nukleosidanaloger
WO1993017651A3 (de) Antivirale nucleosidanaloge, ihre herstellung und ihre verwendung
ATE303154T1 (de) Verwendung von einem trifluridin derivat allein oder in kombination mit einem thymidin- phosphorylase-hemmer zur behandlung von hiv
TW371662B (en) Antiviral acyclic phosphonomethoxyalkyl substituted alkenyl purine and pyrimidine derivatives
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
ZA991029B (en) Composition and methods for treatment of hiv infections.
WO2000041463A3 (en) Combination of hepatitis b vaccine with antiviral agents
IE893991L (en) 2',3'-dideoxypurine nucleoside/purine nucleoside¹phosphorylase inhibitor combination therapy and composition
AP9300513A0 (en) Compositions for the treatment of infection and disease caused by hepatitis b virus(hbv)
DK0625158T3 (da) Terapeutiske nucleosider af 2',3'-dideoxy-3'-fluorpurinrækken
EP0316592A3 (en) 3'-fluoro-2',3'-dideoxyuridine, and its therapeutic application
MY137298A (en) Therapeutic nucleosides
EP0362755A3 (en) Human cytotoxic t-cell clone and antibody thereto

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU